The Future of Precision Medicine: Unlocking the Potential of AI and Genomics
Understanding Long COVID and ME/CFS
March 15th marked International Long COVID Awareness Day, highlighting the debilitating condition that affects at least 65 million people globally. The annual rise in cases creates a healthcare burden exceeding $1 trillion. Long COVID shares significant similarities with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a complex chronic illness characterized by profound fatigue that worsens with physical or mental activity. Both conditions are notoriously difficult to diagnose and treat due to their varied symptoms and affected organs.
Despite their enormous personal and public health impacts, accurate diagnostic tools and effective treatments remain elusive. This lack of understanding has led to widespread misunderstanding, lack of awareness, and even denial of these diseases within clinical and social care communities, further harming sufferers.
PrecisionLife: Revolutionizing Disease Understanding
UK-based PrecisionLife is leveraging AI and combinatorial analytics to uncover deeper genetic associations than traditional methods. This approach explains how complex diseases manifest in patients and uncovers hidden patterns in high-dimensional, complex patient data. This can lead to breakthroughs in diagnostics, drug discovery, and precision medicine.
Transforming Disease Understanding through Advanced Data Analytics
PrecisionLife’s AI-driven approach goes beyond traditional genome-wide association studies (GWAS) by identifying combinations of genetic and non-genetic factors that drive disease in different patient subgroups. Co-founder and CEO Steve Gardner explains the technological foundation of the company:
"Technologically, we reimagine how you analyse data. We bring together two sets of technology: one that I had developed over the last 20 years and another that my co-founder, a mathematician and computer scientist, had been developing for even longer—actually 30 years. We realised that if we put those two things together, we would actually have a way of dealing with these hyper-complex, big patient datasets with all of the genomic information, all the multi-omics, proteomics, epigenetics, and everything else like that, and correlating it with things like longitudinal electronic medical records (EMR) or electronic health records (EHR) and epidemiological and environmental information."
Tackling Highly Complex Diseases
PrecisionLife is tackling highly complex diseases like Alzheimer’s, long-term COVID-19, schizophrenia, and endometriosis. These conditions are influenced by a network of genetic and non-genetic components, making them challenging to diagnose and treat.
Gardner calls ME/CFS "the poster child for hard diseases." He explains that there are many different genetic and non-genetic components within these diseases that influence risk, trigger disease, and show how the disease will manifest itself in individual patients. This level of understanding was not possible with traditional genetic analysis.
Key Genetic Discoveries in COVID, Long COVID, and ME/CFS
PrecisionLife has made significant strides in identifying genetic risk factors for COVID-19, Long COVID, and ME/CFS. In 2020, it identified 68 novel gene targets linked to severe COVID-19, of which 70% were later validated. This resulted in 29 opportunities for approved drugs and candidates that could be repurposed as COVID-19 treatments. Thirteen of these drug candidates were evaluated in clinical trials.
In 2022, PrecisionLife provided the first replicable genetic risk factors for ME/CFS in over 30 years, identifying 14 genes and 199 SNPs, explaining 91% of studied cases. In mid-2023, PrecisionLife accessed Sano Genetics’ GOLD long COVID patient dataset and identified over 5,000 SNPs and 73 genes associated with long COVID. Nine of these genes were also found in the original 14 genes from the ME/CFS analysis.
First-Ever Replicated Genetic Associations for ME/CFS & Long COVID Discovered
PrecisionLife is collaborating with the Metrodora Foundation and its Institute in Salt Lake City, Utah. The Metrodora Foundation aims to bring researchers, doctors, and patients together to rapidly improve diagnostics, treatments, and outcomes in complex conditions like ME/CFS and long COVID. PrecisionLife is running a series of clinical studies on 1,000 patients—500 with ME and 500 with long COVID.
Gardner described the progress as remarkable: "We identified and published the first-ever replicated genetic associations in both ME/CFS and Long COVID. We have started returning results to Metrodora patients based on the specific disease risk signatures a patient has and the symptoms they are most likely to experience. Patients come to us, and they say, ‘this is brilliant. You know, it’s the first time a test has reflected my personal view of what’s going wrong in my disease.’ And clinicians love it because it guides them to amending therapy."
The Potential of Personalized Medicine
Gardner highlights the potential of personalized medicine: "Just think about this: clinically validated novel targets and the ability to select patients who will benefit from drugs modulating that target. That’s incredible. It’s like the NHS-led RECOVERY trial in COVID-19 that discovered dexamethasone—but on steroids—because we’re using genetic evidence to pick the most promising treatments."
Expanding the Scope of PrecisionLife’s Work
PrecisionLife’s insights can optimize patient triage and improve early disease identification and clinical decision-making. For example, in the case of endometriosis, it takes 8–10 years for a confirmed diagnosis via surgery. PrecisionLife aims to turn this into a buccal swab that reports in two weeks and refers a patient accurately to a gynecologist.
Additionally, PrecisionLife’s insights can optimize patient triage. Gardner shared: "For example, we’re working with the healthcare system where 5,000 patients are referred to rheumatology yearly due to a non-specific ANA test. Only 10% actually have a rheumatological condition. That’s a massive misclassification problem blocking the system."
Licensing and Scalability
Rather than building its own diagnostic business, PrecisionLife is licensing its tests and decision support systems to existing healthcare infrastructures. Gardner explains: "We don’t want to build a massive diagnostic business ourselves. The platforms we use are standard and available globally. We can license the content and clinical decision support system to operate these tests across multiple markets. And what’s exciting is that it’s almost disease-agnostic. This model allows for scalability, making their technology accessible across multiple conditions and healthcare markets worldwide."
The Future of Disease Prevention: ‘Actively Protective’ Genes
PrecisionLife is pioneering a new approach to disease prevention by identifying ‘actively protective’ genes—genetic factors that shield certain high-risk individuals from developing diseases. Traditionally, genetic research focuses on identifying disease-causing mutations, but this new method flips the process, searching instead for individuals who should have developed a disease but remain healthy despite having high genetic risk and exposure to disease triggers.
These findings open up possibilities for new preventative therapies, including drug targets that function similarly to statins, which lower cholesterol to prevent heart disease. Additionally, some of these protective genes could be harnessed for mRNA-based treatments, using the same technology as COVID-19 vaccines to boost natural disease resistance. This could lead to personalized protective treatments, extending healthspan and improving quality of life for high-risk individuals before disease ever develops.
Table: Key Genetic Discoveries by PrecisionLife
| Year | Disease/Condition | Key Findings |
|---|---|---|
| 2020 | Severe COVID-19 | Identified 68 novel gene targets, 70% validated, 29 drug opportunities, 13 in clinical trials |
| 2022 | ME/CFS | First replicable genetic risk factors in 30 years, 14 genes and 199 SNPs identified |
| 2023 | Long COVID | Over 5,000 SNPs and 73 genes associated with long COVID, 9 genes overlap with ME/CFS |
FAQ Section
What is Long COVID and how does it relate to ME/CFS?
Long COVID is a debilitating condition that affects millions of people worldwide, characterized by symptoms that persist long after the initial COVID-19 infection. It shares many similarities with ME/CFS, a chronic illness marked by profound fatigue that worsens with physical or mental activity. Both conditions are difficult to diagnose and treat due to their varied symptoms and affected organs.
How does PrecisionLife use AI and combinatorial analytics?
PrecisionLife leverages AI and combinatorial analytics to uncover deeper genetic associations than traditional methods. This approach identifies combinations of genetic and non-genetic factors that drive disease in different patient subgroups, enabling breakthroughs in diagnostics, drug discovery, and precision medicine.
What are ‘actively protective’ genes?
‘Actively protective’ genes are genetic factors that shield certain high-risk individuals from developing diseases. PrecisionLife is pioneering a new approach to disease prevention by identifying these genes, which could lead to new preventative therapies and personalized protective treatments.
How does PrecisionLife optimize patient triage?
PrecisionLife’s insights can optimize patient triage by improving early disease identification and clinical decision-making. For example, in the case of endometriosis, PrecisionLife aims to reduce the diagnostic time from years to weeks, and in rheumatology, it can help reduce misclassification problems by accurately identifying patients who need specific treatments.
Did You Know?
PrecisionLife’s AI-driven approach has identified over 5,000 SNPs and 73 genes associated with long COVID, providing the strongest genetic evidence for Long COVID to date.
Pro Tips
For healthcare professionals looking to stay ahead of the curve, consider integrating PrecisionLife’s insights into your diagnostic and treatment protocols. This could lead to more accurate diagnoses and targeted therapies, ultimately improving patient outcomes.
Reader Question
How do you think the identification of ‘actively protective’ genes could revolutionize disease prevention and treatment? Share your thoughts in the comments below!
Call to Action
Join the conversation and share your insights on the future of precision medicine. Comment below, explore more articles on our site, or subscribe to our newsletter to stay updated on the latest developments in healthcare and technology.
The post Discoveries in Long COVID and ME/CFS by PrecisionLife appeared first on Archynetys.